<DOC>
	<DOCNO>NCT02359357</DOCNO>
	<brief_summary>To determine safety tolerability single multiple escalate dos FDL169 healthy male subject .</brief_summary>
	<brief_title>FTIH - Single Repeat Oral Doses FDL169 Healthy Volunteers</brief_title>
	<detailed_description>This study first time human study consist two part . Part 1A : Part 1 study randomise , double-blind , placebo-controlled , dose-escalation , first-time-in-human study ass safety , tolerability PK profile follow single oral administration FDL169 healthy male volunteer . Sixty-four ( 64 ) male subject ( 8 per cohort ) include Part 1 study . Up eight dose level FDL169 plan test Part 1 study . Part 1B : Open label . Following completion Part 1A study , additional cohort 8 subject receive single dose FDL169 fast feed state Part 2 : Part 2 study randomise , double-blind , placebo-controlled , dose-escalation study ass safety , tolerability PK profile follow multiple oral administration FDL169 healthy male subject . Forty-eight male subject , cohort twelve , include Part 2 study . It plan test four dose level FDL169 Part 2 .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Healthy male subject age 18 45 year fulfil standard safety screen assessment study ( haematology/biochemistry , urinalysis , 12lead electrocardiogram ( ECG ) , vital sign oral temperature ) opinion Investigator , medically suitable participate study . Male subject partner must willing use effective method contraception first dose investigational medicinal product ( IMP ) 3 month last dose IMP . 1 . Participation New Chemical Entity clinical study within previous 4 month market drug clinical study within previous 3 month . 2 . Subjects history presence clinically significant cardiovascular , pulmonary , renal , hepatic , haematologic , gastrointestinal ( endocrine immunologic disease ) , Screening . 3 . Donation 500 mL blood within previous 3 month . 4 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement within 21 day ( 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator Flatley Discovery Labs Medical Monitor medication interfere study procedure compromise subject safety . 5 . Smoking use tobacco product substitute equivalent &gt; 15 cigarettes/day . 6 . Any subject attempt father child within 3 month FollowUp Visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>